Foamix Pharmaceuticals Ltd. Forms 3, 4 and 5: Restricted Stock Units and Performance Rights
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 38 rows, 38 shown. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2018-07-13: Reporting owner Hirsch Stanley; Form 4; Security Restricted Share Units; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2018-01-18: Reporting owner Eini Meir; Form 3; Security Restricted Share Units; Transaction Holding.
- 2018-01-18: Reporting owner Eini Meir; Form 3; Security Restricted Share Units; Transaction Holding.
- 2018-01-18: Reporting owner Eini Meir; Form 3; Security Restricted Share Units; Transaction Holding.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2018-07-13 | Hirsch Stanley Director | 4 | Restricted Share Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,616 0 owned after | $0.00 | 2018-07-13 | |
| 2018-01-18 holding as of filing | Eini Meir Other (Observer to Board of Directors) | 3 | Restricted Share Units Derivative · Direct · (m) | Holding | no price filed | 2018-01-18 | ||
| 2018-01-18 holding as of filing | Eini Meir Other (Observer to Board of Directors) | 3 | Restricted Share Units Derivative · Direct · (m) | Holding | no price filed | 2018-01-18 | ||
| 2018-01-18 holding as of filing | Eini Meir Other (Observer to Board of Directors) | 3 | Restricted Share Units Derivative · Direct · (m) | Holding | no price filed | 2018-01-18 | ||
| 2018-01-15 | Schuz David Officer (VP IP) | 4 | Restricted Share Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −562 0 owned after | $0.00 | 2018-01-24 | |
| 2018-01-15 | Shirvan Mitchell Officer (VP Innovation & Discovery) | 4 | Restricted Share Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −562 0 owned after | $0.00 | 2018-01-24 | |
| 2018-01-15 | Hadar Ilan Officer (CFO & Country Manager) | 4 | Restricted Share Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −562 0 owned after | $0.00 | 2018-01-24 | |
| 2018-01-15 | Hazot Yohan Officer (VP Pharmaceutical Development) | 4 | Restricted Share Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −562 0 owned after | $0.00 | 2018-01-24 | |
| 2018-01-15 | Eini Meir Other (Observer to the Board) | 4 | Restricted Share Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,125 4,500 owned after | $0.00 | 2018-01-18 | |
| 2018-01-11 holding as of filing | Hazot Yohan Officer (VP Pharmaceutical Development) | 3 | Restricted Share Units Derivative · Direct | Holding | no price filed | 2018-01-11 | ||
| 2018-01-11 holding as of filing | Hazot Yohan Officer (VP Pharmaceutical Development) | 3 | Restricted Share Units Derivative · Direct | Holding | no price filed | 2018-01-11 | ||
| 2018-01-11 holding as of filing | Hadar Ilan Officer (Country Manager and CFO) | 3 | Restricted Share Units Derivative · Direct | Holding | no price filed | 2018-01-11 | ||
| 2018-01-11 holding as of filing | Hadar Ilan Officer (Country Manager and CFO) | 3 | Restricted Share Units Derivative · Direct | Holding | no price filed | 2018-01-11 | ||
| 2018-01-11 holding as of filing | Hadar Ilan Officer (Country Manager and CFO) | 3 | Restricted Share Units Derivative · Direct | Holding | no price filed | 2018-01-11 | ||
| 2018-01-11 holding as of filing | Hadar Ilan Officer (Country Manager and CFO) | 3 | Restricted Share Units Derivative · Direct | Holding | no price filed | 2018-01-11 | ||
| 2018-01-11 holding as of filing | Schuz David Officer (VP IP) | 3 | Restricted Share Units Derivative · Direct | Holding | no price filed | 2018-01-11 | ||
| 2018-01-11 holding as of filing | Schuz David Officer (VP IP) | 3 | Restricted Share Units Derivative · Direct | Holding | no price filed | 2018-01-11 | ||
| 2018-01-11 holding as of filing | Hirsch Stanley | 3 | Restricted Share Units Derivative · Direct · (m) | Holding | no price filed | 2018-01-11 | ||
| 2018-01-11 holding as of filing | Shirvan Mitchell Officer (VP Innovation & Discovery) | 3 | Restricted Share Units Derivative · Direct | Holding | no price filed | 2018-01-11 | ||
| 2018-01-11 holding as of filing | Shirvan Mitchell Officer (VP Innovation & Discovery) | 3 | Restricted Share Units Derivative · Direct | Holding | no price filed | 2018-01-11 | ||
| 2018-01-11 holding as of filing | Howard Alvin D Officer (VP Regulatory) | 3 | Restricted Share Units Derivative · Direct | Holding | no price filed | 2018-01-11 | ||
| 2018-01-11 holding as of filing | Howard Alvin D Officer (VP Regulatory) | 3 | Restricted Share Units Derivative · Direct | Holding | no price filed | 2018-01-11 | ||
| 2018-01-11 holding as of filing | Tamarkin Dov Director | 3 | Restricted Share Units Derivative · Direct · (m) | Holding | no price filed | 2018-01-11 | ||
| 2018-01-11 holding as of filing | Domzalski David Officer (CEO) | 3 | Restricted Share Units Derivative · Direct | Holding | no price filed | 2018-01-11 | ||
| 2018-01-11 holding as of filing | Domzalski David Officer (CEO) | 3 | Restricted Share Units Derivative · Direct | Holding | no price filed | 2018-01-11 | ||
| 2018-01-11 holding as of filing | Domzalski David Officer (CEO) | 3 | Restricted Share Units Derivative · Direct | Holding | no price filed | 2018-01-11 | ||
| 2018-01-11 holding as of filing | Domzalski David Officer (CEO) | 3 | Restricted Share Units Derivative · Direct | Holding | no price filed | 2018-01-11 | ||
| 2018-01-11 holding as of filing | Stuart Iain Officer (SVP R&D) | 3 | Restricted Share Units Derivative · Direct | Holding | no price filed | 2018-01-11 | ||
| 2018-01-11 holding as of filing | KAZANCHYAN ANNA Director | 3 | Restricted Share Units Derivative · Direct | Holding | no price filed | 2018-01-11 | ||
| 2018-01-11 holding as of filing | Elliot Russel Officer (VP Drug Development) | 3 | Restricted Share Units Derivative · Direct | Holding | no price filed | 2018-01-11 | ||
| 2018-01-01 | Schuz David Officer (VP IP) | 4 | Restricted Share Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,745 0 owned after | $0.00 | 2018-01-24 | |
| 2018-01-01 | Shirvan Mitchell Officer (VP Innovation & Discovery) | 4 | Restricted Share Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,745 0 owned after | $0.00 | 2018-01-24 | |
| 2018-01-01 | Hadar Ilan Officer (CFO & Country Manager) | 4 | Restricted Share Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,032 0 owned after | $0.00 | 2018-01-24 | |
| 2018-01-01 | Elliott Russell P. Officer (VP Drug Development) | 4 | Restricted Share Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,372 0 owned after | $0.00 | 2018-01-24 | |
| 2018-01-01 | Domzalski David Director, Officer (CEO) | 4 | Restricted Share Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,948 0 owned after | $0.00 | 2018-01-24 | |
| 2018-01-01 | Howard Alvin D Officer (VP Regulatory) | 4 | Restricted Share Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,288 0 owned after | $0.00 | 2018-01-24 | |
| 2018-01-01 | Hazot Yohan Officer (VP Pharmaceutical Development) | 4 | Restricted Share Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,575 0 owned after | $0.00 | 2018-01-24 | |
| 2018-01-01 | Eini Meir Other (Observer to the Board) | 4 | Restricted Share Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,032 15,098 owned after | $0.00 | 2018-01-18 |